Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
13%
Acute Myeloid Leukemia
8%
Anticoagulant Agent
8%
Antifungal Therapy
13%
Azacitidine
16%
Bortezomib
33%
Busulfan
26%
Chronic Myeloid Leukemia
18%
Clinical Feature
14%
Cyclophosphamide
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Decitabine
16%
Dexamethasone
32%
Diffuse Large B Cell Lymphoma
30%
Disease Course
8%
Doxorubicin
20%
Febrile Neutropenia
14%
Fludarabine
10%
Fluorouracil
10%
Frailty
7%
Hydroxycarbamide
7%
Imatinib
36%
Itraconazole
13%
Lenalidomide
25%
Leukotriene B4
10%
Melphalan
20%
Multiple Myeloma
100%
Myelodysplastic Syndrome
33%
Myeloid Leukemia
13%
Myeloma
14%
NK T Cell Lymphoma
10%
Observational Study
13%
Overall Survival
72%
Paroxysmal Nocturnal Hemoglobinuria
10%
Pomalidomide
10%
Prednisone
12%
Progression Free Survival
31%
Promyelocytic Leukemia
10%
Radotinib
10%
Reactive Oxygen Metabolite
10%
Recurrence Free Survival
11%
Remission
14%
Rituximab
33%
Survival Rate
17%
Thalidomide
36%
Thrombocythemia
10%
Thromboembolism
12%
Thrombosis
7%
Venous Thromboembolism
26%
Vincristine
11%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
10%
Acute Myeloid Leukemia
33%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Aplastic Anemia
8%
Autologous Stem Cell Transplantation
43%
Bortezomib
29%
CHOP
8%
Clinical Feature
20%
Cord Blood
13%
Cyclophosphamide
14%
Cytarabine
12%
Dexamethasone
18%
Diffuse Large B-Cell Lymphoma
45%
Disease Free Survival
8%
Doxorubicin
20%
Elderly Patient
8%
Epstein Barr Virus
9%
Febrile Neutropenia
8%
Hazard Ratio
11%
Hematopoietic Cell
11%
Hematopoietic Stem Cell Transplantation
8%
Idiopathic Thrombocytopenic Purpura
23%
Imatinib
20%
International Prognostic Index
14%
Lactate Dehydrogenase
14%
Melphalan
8%
Multiple Myeloma
86%
Myelodysplastic Syndrome
20%
Myeloma
17%
Myeloproliferative Neoplasm
10%
Neutrophil
12%
NK T Cell Lymphoma
16%
Observational Study
14%
Overall Survival
80%
Paroxysmal Nocturnal Hemoglobinuria
10%
Platelet
9%
Predictive Factor
10%
Prednisone
11%
Prognostic Factor
54%
Progression Free Survival
38%
Recurrence Free Survival
10%
Retrospective Study
9%
Rituximab
19%
Stem Cell Therapy
11%
Survival Rate
15%
T-Cell Lymphoma
9%
Thromboembolism
12%
Thrombosis
10%
Venous Thromboembolism
30%
Vincristine
13%
Biochemistry, Genetics and Molecular Biology
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Autologous Stem Cell Transplantation
10%
Azacitidine
16%
B Cell
12%
Busulfan
6%
CD34
7%
CD44
6%
Chromosomal Abnormalities
12%
Chromosome 13
6%
Chromosome 20q
8%
Chromosome 5
7%
Chromosome 7
7%
Chromosome Analysis
6%
Clonal Evolution
7%
Conditioning
6%
Core Binding Factor
20%
Cytogenetics
43%
Decitabine
20%
Dexamethasone
15%
Doxorubicin
9%
ERCC1
6%
Event Free Survival
13%
Exon
6%
Fluorescence in Situ Hybridization
23%
Genotyping
20%
Hematopoietic Cell
6%
High Risk Population
9%
Human Leukocyte Antigen
6%
Imatinib
13%
Interphase
11%
Karyotype
19%
Karyotyping
44%
Lactate Dehydrogenase
8%
Loss of Heterozygosity
18%
Metaphase
35%
Monosomy
6%
Myeloid
64%
Overall Survival
55%
Philadelphia Chromosome
6%
Platelet Count
11%
Polymorphonuclear Cell
8%
Precursor
6%
Progression Free Survival
12%
Ring Chromosome
6%
Rituximab
7%
RUNX1
8%
RUNX1T1
8%
Single Nucleotide Polymorphism
27%
Single-Nucleotide Polymorphism
67%
Somatic Mutation
8%
